Charles Ryan, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Charles Ryan, MD

Professor of Clinical Medicine and Urology
Program Leader, Genitourinary Medical Oncology

Thomas Perkins Distinguished Professor in Cancer Research, UCSF

Phone: (415) 476-4616 (appts)
Box 3211, UCSF
San Francisco, CA 94143-3211

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Prostate Cancer

Research Summary

Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.

His clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract.

His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, insulin growth factor inhibitors, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials Dr Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients.

Dr Ryan is a member of several honor societies and is the recipient of a Leadership and Service Award and the John Kimberly Curtis Award from the University of Wisconsin Medical School. He received the American College of Physicians/ American Society of Internal Medicine Evergreen Award in 2000 and the American Society of Clinical Oncology Merit Award and Cancer And Leukemia Group B: Young Investigator Award, both in 2003. He was awarded the Donald Coffey Career Development Award from the Prostate Cancer Foundation in 2006, a California Coalition to Cure Prostate Cancer Award in 2007 and received the Mentor Award from the Division of Hematology/Oncology in 2011.

Education

Marquette University, BA, 1991, Philosophy
University of Wisconsin - Madison, MD, 1996, Medicine
University of Wisconsin Hospital and Clinics, 1996-97, Intern, Medicine
University of Wisconsin Hospital and Clinics, 1997-99, Resident, Medicine
University of Wisconsin Hospital and Clinics, 1999-00, Chief Resident, Medicine
Memorial Sloan-Kettering Cancer Center, 2000-03, Fellow, Medical Oncology


Professional Experience

  • 2003-2008
    Assistant Clinical Professor of Medicine, UC San Francisco
  • 2008-2014
    Associate Clinical Professor of Medicine, UC San Francisco
  • 2014-present
    Professor of Clinical Medicine and Urology, UC San Francisco

Honors & Awards

  • 1991
    Alpha Sigma Nu, National Jesuit University Academic Honor Society
  • 1991
    Phi Beta Kappa, Marquette University
  • 1994
    Leadership and Service Award, University of Wisconsin Medical School
  • 1996
    John Kimberly Curtis Award, University of Wisconsin Medical School
  • 2000
    Evergreen Award, American College of Physicians-American Society of Internal Medicine
  • 2002
    ASCO Merit Award
  • 2002
    Cancer And Leukemia Group B Young Investigator Award
  • 2006
    Prostate Cancer Foundation: Donald Coffey Career Development Award
  • 2007
    California Coalition to Cure Prostate Cancer Award

Selected Publications

  1. Dhawan M, Ryan CJ. Utility of novel androgen receptor therapies in the real world: A nuanced approach. Urol Oncol. 2016 Aug; 34(8):340-7.
    View on PubMed
  2. Dhawan M, Ryan CJ, Ashworth A. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. Oncologist. 2016 Aug; 21(8):940-5.
    View on PubMed
  3. Ryan CJ. Targeting the Androgen Receptor: Remaining questions and future directions. Urol Oncol. 2016 Aug; 34(8):339.
    View on PubMed
  4. Fizazi K, De Porre P, Londhe A, McGowan T, Ryan CJ. Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients. Eur Urol. 2016 Aug; 70(2):e42.
    View on PubMed
  5. Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE, Ryan CJ, Scher HI, Shore ND, De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, Montgomery B. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 Sep; 70(3):438-44.
    View on PubMed
  6. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 Aug; 34(8):368-74.
    View on PubMed
  7. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
    View on PubMed
  8. Borno H, Siegel A, Ryan C. The problem of representativeness of clinical trial participants: understanding the role of hidden costs. J Health Serv Res Policy. 2016 Jul; 21(3):145-6.
    View on PubMed
  9. Kim W, Ryan CJ. Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. J Comp Eff Res. 2016 Jan; 5(1):5-7.
    View on PubMed
  10. Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016 Mar; 27(3):454-60.
    View on PubMed
  11. Fizazi K, Flaig TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, Ryan CJ, Kheoh T, Li J, Todd MB, Griffin TW, Molina A, Ohlmann CH. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016 Apr; 27(4):699-705.
    View on PubMed
  12. Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 May; 69(5):924-32.
    View on PubMed
  13. Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J Urol. 2015 Nov; 194(5):1277-84.
    View on PubMed
  14. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1.
    View on PubMed
  15. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):772-99.
    View on PubMed
  16. Beard CJ, Gupta S, Motzer RJ, O'Donnell EK, Plimack ER, Margolin KA, Ryan CJ, Sheinfeld J, Feldman DR. Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. J Natl Compr Canc Netw. 2015 Jun; 13(6):811-22.
    View on PubMed
  17. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7.
    View on PubMed
  18. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16.
    View on PubMed
  19. Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res. 2015 Jul 15; 21(14):3170-7.
    View on PubMed
  20. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):151-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI